Role of RUNX3 in suppressing metastasis and angiogenesis of human prostate cancer

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Chen, Feifei ^a   Wang, Meng ^a   Bai, Jin ^a   Liu, Qinghua ^a   Xi, Yaguang ^a,b   Li, Wang ^a   Zheng, Junnian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR RUNX3; VASCULOTROPIN; RUNX3 PROTEIN, HUMAN; SMALL INTERFERING RNA; TIMP2 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STAGING; CELL INVASION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TISSUE MICROARRAY; TUMOR VASCULARIZATION; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CARCINOMA; CELL MOTION; CYTOLOGY; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; SECONDARY; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA; CELL MOVEMENT; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899800084     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086917     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 62: 283-298.
2. Ohlmann CH, Siemer S, Stockle M (2012) [Resection of metastases from prostate cancer]. Urologe A 51: 363-367.
3. Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147: 275-292.
4. Ogawa E, Maruyama M, Kagoshima H, Inuzuka M, Lu J, et al. (1993) PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc Natl Acad Sci U S A 90: 6859-6863. (Pubitemid 23207313)
5. Lund AH, van Lohuizen M (2002) RUNX: a trilogy of cancer genes. Cancer Cell 1: 213-215. (Pubitemid 41039143)
6. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, et al. (2009) Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 1796: 315-331.
7. Bae SC, Takahashi E, Zhang YW, Ogawa E, Shigesada K, et al. (1995) Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain. Gene 159: 245-248.
8. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, et al. (2006) RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520. (Pubitemid 44085605)
9. Mei PJ, Bai J, Liu H, Li C, Wu YP, et al. (2011) RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol 137: 1823-1830.
10. Sakakura C, Hasegawa K, Miyagawa K, Nakashima S, Yoshikawa T, et al. (2005) Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res 11: 6479-6488. (Pubitemid 41338985)
11. Zhang Z, Chen G, Cheng Y, Martinka M, Li G (2011) Prognostic significance of RUNX3 expression in human melanoma. Cancer 117: 2719-2727.
12. Hsu PI, Hsieh HL, Lee J, Lin LF, Chen HC, et al. (2009) Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann Surg Oncol 16: 1686-1694.
13. Chen F, Bai J, Li W, Mei P, Liu H, et al. (2013) RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma. PLoS One 8: e56241.
14. Chung MS, Lee SH, Lee DH, Chung BH (2013) Evaluation of the 7th American Joint Committee on cancer TNM staging system for prostate cancer in point of classification of bladder neck invasion. Jpn J Clin Oncol 43: 184-188.
15. Garg M, Kanojia D, Salhan S, Suri S, Gupta A, et al. (2009) Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer 115: 2671-2683.
16. White KY, Rodemich L, Nyalwidhe JO, Comunale MA, Clements MA, et al. (2009) Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J Proteome Res 8: 620-630.
17. Wang Q, Zheng JY, Kreth J, Yan X, Kamata M, et al. (2009) Regulation of prostate-specific antigen expression by the junctional adhesion molecule A. Urology 73: 1119-1125.
18. Lee CW, Ito K, Ito Y (2010) Role of RUNX3 in bone morphogenetic protein signaling in colorectal cancer. Cancer Res 70: 4243-4252.
19. Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, et al. (2004) Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 84: 479-484. (Pubitemid 41656475)
20. Richiardi L, Fiano V, Vizzini L, De Marco L, Delsedime L, et al. (2009) Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 27: 3161-3168.
21. Mocarska A, Staroslawska E, Iwonna ZC, Brzozowska A, Losicki M, et al. (2012) [Diagnostic imaging of the prostate cancer]. Pol Merkur Lekarski 33: 357-363.
22. Ito K (2012) [Tumor suppressive functions of RUNX3 in gastric carcinogenesis]. Seikagaku 84: 278-282.
23. Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, et al. (2005) RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 65: 9347-9354. (Pubitemid 41508002)
24. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34. (Pubitemid 43723979)
25. Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, et al. (2008) Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 14: 6610-6617.
26. Wang Q, Diao X, Sun J, Chen Z (2011) Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int 35: 897-904.
27. Zhang XY, Hong BF, Chen GF, Lu YL, Zhong M (2005) [Significance of MMP2 and MMP9 expression in prostate cancer]. Zhonghua Nan Ke Xue 11: 359-361, 364.
28. Chen Y, Wei X, Guo C, Jin H, Han Z, et al. (2011) Runx3 suppresses gastric cancer metastasis through inactivation of MMP9 by upregulation of TIMP-1. Int J Cancer 129: 1586-1598.
29. Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, et al. (2006) MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 10: 499-510. (Pubitemid 44872701)
30. Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378: 151-160.
31. Pulukuri SM, Patibandla S, Patel J, Estes N, Rao JS (2007) Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene 26: 5229-5237. (Pubitemid 47237624)
32. Waleh NS, Murphy BJ, Zaveri NT (2010) Increase in tissue inhibitor of metalloproteinase-2 (TIMP-2) levels and inhibition of MMP-2 activity in a metastatic breast cancer cell line by an anti-invasive small molecule SR13179. Cancer Lett 289: 111-118.
33. Hussain Z, Khan MI, Shahid M, Almajhdi FN (2013) S-adenosylmethionine, a methyl donor, up regulates tissue inhibitor of metalloproteinase-2 in colorectal cancer. Genet Mol Res 12: 1106-1118.
34. Zhang L, Zeng D, Huang H, Wang J, Tao Q, et al. (2010) Tissue inhibitor of metalloproteinase-2 inhibits ameloblastoma growth in a new mouse xenograft disease model. J Oral Pathol Med 39: 94-102.
35. O'Hurley G, Perry AS, O'Grady A, Loftus B, Smyth P, et al. (2011) The role of secreted frizzled-related protein 2 expression in prostate cancer. Histopathology 59: 1240-1248.
36. Folkman J (1997) Angiogenesis and angiogenesis inhibition: an overview. EXS 79: 1-8.
37. Ellis LM, Rosen L, Gordon MS (2006) Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol 4: suppl 1-10; quz 11-12.
38. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, et al. (2001) Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61: 4143-4154. (Pubitemid 32720983)
39. Xie K, Wei D, Shi Q, Huang S (2004) Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 15: 297-324. (Pubitemid 39140697)
40. McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5 Suppl 1: 3-10.
41. Cao Y, E G, Wang E, Pal K, Dutta SK, et al. (2012) VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res 72: 3912-3918.
42. Pal S, Datta K, Mukhopadhyay D (2001) Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 61: 6952-6957. (Pubitemid 32896524)
43. Peng Z, Wei D, Wang L, Tang H, Zhang J, et al. (2006) RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin Cancer Res 12: 6386-6394. (Pubitemid 44799709)